NCT07369986 (IMMUNE-SAVE) is a Phase 2 clinical trial of Iparomlimab and Tuvonralimab (QL1706) in Endometrial Cancer, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT07369986?

NCT07369986 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What drugs are being tested in NCT07369986?

Interventions in NCT07369986: Iparomlimab and Tuvonralimab (QL1706).

What condition does NCT07369986 study?

NCT07369986 studies Endometrial Cancer, Immunotherapy, Mismatch Repair Deficiency.

Is NCT07369986 still recruiting?

NCT07369986 is currently not yet recruiting. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT07369986: IMMUNE-SAVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Not yet recruiting Phase 2 Last updated 27 January 2026

What this trial tests

Phase 2 trial testing Iparomlimab and Tuvonralimab (QL1706) in Endometrial Cancer in 30 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 March 2026
Primary completion	31 December 2027
Estimated completion	31 December 2028

Drugs / interventions tested

Iparomlimab and Tuvonralimab (QL1706) — full drug profile →

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →
Immunotherapy — all drugs for Immunotherapy →
Mismatch Repair Deficiency — all drugs for Mismatch Repair Deficiency →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

18 and older, female only, with Endometrial Cancer or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Iparomlimab and Tuvonralimab (QL1706)

Trials testing the same drug.

NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07315854 — Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric · Phase 2 · recruiting
NCT07117877 — Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or · Phase 2 · not yet recruiting
NCT06954116 — Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence · Phase 2 · not yet recruiting

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting
NCT06832800 — Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07369986 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07369986.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing